Cite
MLA Citation
Todd M. Cooper et al.. “A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10‐03).” Pediatric blood & cancer, vol. 64, no. 8, 2017, p. n/a. http://access.bl.uk/ark:/81055/vdc_100047416620.0x000009